|Click on "►" to expand:|
 BRAND NAMES
 MECHANISM OF ACTION
The principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. (Rufinamide significantly slows sodium channel recovery from inactivation)
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults.
Rufinamide should be given with food. Tablets can be administered whole, as half tablets, or crushed.
- Children four years and older with Lennox-Gastaut syndrome (LGS): Treatment should be initiated at a daily dose of approximately 10 mg/kg/day administered in two equally divided doses. The dose should be increased by approximately 10 mg/kg increments every other day to a target dose of 45 mg/kg/day or 3200 mg/day, whichever is less, administered in two equally divided doses.
- Adults with Lennox-Gastaut syndrome (LGS): Treatment should be initiated at a daily dose of 400-800 mg/day administered in two equally divided doses. The dose should be increased by 400-800 mg every other day until a maximum dose of 3200mg/day, administered in two equally divided doses is reached.
See Full Prescribing Information for dosing in patients with renal impairment, hemodialysis, hepatic impairment, and for those patients on valproate.
 DOSAGE FORMS AND STRENGTHS
- 200mg, 400mg, film-coated tablets with a score on both sides.
- 40 mg/mL oral suspension
- Patientswith Familial Short QT syndrome
 PREGNANCY AND LACTATION
 SIDE EFFECTS
The most commonly observed adverse reactions were headache, dizziness, fatigue, somnolence, and nausea.